<DOC>
	<DOCNO>NCT01098032</DOCNO>
	<brief_summary>The purpose present study assess role RenalGuard System compare optimal strategy ( sodium bicarbonate infusion plus N-acetylcysteine ( NAC ) ) high very-high risk patient prevent contrast-induced acute kidney injury contrast induce acute kidney injury ( CI-AKI ) . Consecutive patient chronic kidney disease , refer institution coronary and/or peripheral procedure , randomly assign 1 ) prophylactic administration sodium bicarbonate plus NAC ( Systemic alone therapy group ; n &gt; 133 ) 2 ) RenalGuard System treatment ( RenalGuard group ; n &gt; 133 ) . All enrol patient must estimate glomerular filtration rate &lt; 30 ml/min/1.73 m2 and/or contrast nephropathy risk score ≥11 ) . In case iodixanol ( iso-osmolar , non ionic contrast agent ) administer . The primary end point increase &gt; =0.3 mg/dL creatinine concentration 48 hour procedure . This study give important answer prevent CI-AKI high very-high risk patient undergo contrast medium exposure .</brief_summary>
	<brief_title>RenalGuard System Contrast Media</brief_title>
	<detailed_description>The strategy volume supplementation sodium bicarbonate plus N-acetylcysteine ( NAC ) seem optimal pharmacological approach prevent contrast induce acute kidney injury ( CI-AKI ) patient medium-to-high risk . Whether prophylactic strategy effective high very-high risk patient unknown . In subset patient potential protective effect therapeutic advantage local delivery protective compound investigate . The RenalGuard™ System ( PLC Medical Systes , Inc. ) real-time measurement real time match fluid replacement device design accommodate RenalGuard Therapy . The RenalGuard Therapy base theory create maintain high urine output beneficial patient undergo image procedure contrast agent use . This allow body rapidly eliminate contrast , reduce toxic effect . The RenalGuard System seem ideal prevention CI-AKI , allow optimal urine flow rate &gt; 150 ml/h ( ideally &gt; 300 ml/h ) . Preliminary data suggest RenalGuard System , increase urine flow rate ≥ 300 ml/h , allow quick renal first-pass elimination therefore reduces risk contrast nephropathy . The potential benefit RenalGuard Therapy intend reduce incidence CI-AKI via combination know physiological effect high urine output include : ) low concentration contrast kidney , b ) rapid transit contrast kidney , c ) less overall exposure toxic contrast , ) potential reduction oxygen consumption medulla kidney . No randomized study perform assess role RenalGuard System compare optimal strategy ( sodium bicarbonate infusion plus NAC ) high very-high risk patient prevent CI-AKI .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<criteria>1 . Age &gt; =18 year 2 . Chronic kidney disease ( estimate glomerular filtration rate &lt; =30 ml/min/1.72 m2 ) and/or 3 . Risk score contrast nephropathy ≥11 ( accord Mehran score ; J Am Coll Cardiol 2004 ; 44 : 13931399 ) 1 . Pregnancy 2 . Heart failure ( NYHA functional class IIIIV ) 3 . Acute pulmonary edema 4 . Acute myocardial infarction 5 . Recent ( &lt; =2 day ) contrast medium exposure 6 . Patients enrol concomitant study 7 . Administration theophylline , dopamine , mannitol fenoldopam . 8 . Endstage CKD ( patient chronic dialysis ) 9 . Systemic hypotension ( systolic blood pressure &lt; 100 mg/dl ) . 10 . Multiple myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Contrast medium</keyword>
	<keyword>Kidney</keyword>
	<keyword>Complication</keyword>
</DOC>